Cochrane · systematic review · CD007779
Levomepromazine for schizophrenia
Sivaraman, P, Rattehalli, RD, Jayaram, MB · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 16.7%Low 5 · 41.7%Moderate 5 · 41.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Levomepromazine compared to Typical antipsychotics for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early ‐ short term ‐ any reason Levomepromazine vs Typical antipsychotics | RR 1.11 [0.45, 2.74] | 1 study · 41 participants | Low Downgraded: risk of bias |
Leaving the study early ‐ short term ‐ due to lack of efficacy Levomepromazine vs Typical antipsychotics | RR 0.95 [0.22, 4.18] | 1 study · 41 participants | Low Downgraded: risk of bias |
Leaving the study early ‐ short term ‐ due to adverse events Levomepromazine vs Typical antipsychotics | RR 4.77 [0.24, 93.67] | 1 study · 41 participants | Low Downgraded: risk of bias |
Leaving the study early ‐ medium term ‐ any reason Levomepromazine vs Typical antipsychotics | RR 2 [0.2, 19.62] | 1 study · 28 participants | Very low Downgraded: risk of bias |
Leaving the study early ‐ long term ‐ any reason Levomepromazine vs Typical antipsychotics | RR 0.4 [0.09, 1.81] | 1 study · 38 participants | Moderate Downgraded: risk of bias |
Leaving the study early ‐ long term ‐ due to adverse events Levomepromazine vs Typical antipsychotics | RR 1 [0.07, 14.85] | 1 study · 38 participants | Moderate Downgraded: risk of bias |
Leaving the study early ‐ long term ‐ lost to Levomepromazine vs Typical antipsychotics | RR 1 [0.07, 14.85] | 1 study · 38 participants | Moderate Downgraded: risk of bias |
Levomepromazine compared to Atypical antipsychotics for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early ‐ short term ‐ any reason Levomepromazine vs Atypical antipsychotics | RR 1 [0.67, 1.49] | 2 studies · 106 participants | Low Downgraded: risk of bias |
Leaving the study early ‐ short term ‐ due to adverse events Levomepromazine vs Atypical antipsychotics | RR 5 [0.25, 98.27] | 1 study · 42 participants | Moderate Downgraded: risk of bias |
Leaving the study early ‐ short term ‐ due to lack of efficacy Levomepromazine vs Atypical antipsychotics | RR 0.83 [0.4, 1.74] | 2 studies · 106 participants | Very low Downgraded: risk of bias |
Leaving the study early ‐ short term ‐ due to patient deterioration Levomepromazine vs Atypical antipsychotics | RR 5 [0.25, 98.27] | 1 study · 42 participants | Moderate Downgraded: risk of bias |
Leaving the study early ‐ short term ‐ lost to Levomepromazine vs Atypical antipsychotics | RR 0.33 [0.01, 7.74] | 1 study · 42 participants | Low Downgraded: risk of bias |